Skip to main content

FLGT

Stock

FLGT

Stock
Health Care
Diagnostics & Research

Performance overview

FLGT Price
Price Chart

Forward-looking statistics

Beta
0.73
Risk
43.36%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Company info

SectorHealth Care
IndustryDiagnostics & Research
Employees720
Market cap$607.5M

Fundamentals

Enterprise value$288.8M
Revenue$292.4M
Revenue per employee—
Profit margin-13.94%
Debt to equity0.74

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.33
Dividend per share—
Revenue per share$9.59
Avg trading volume (30 day)$5M
Avg trading volume (10 day)$4M
Put-call ratio—

Macro factor sensitivity

Growth-1.0
Credit+6.6
Liquidity-0.7
Inflation-2.8
Commodities-1.7
Interest Rates-3.1

Valuation

Dividend yield0.00%
PEG Ratio-39.33
Price to sales2.09
P/E Ratio-39.33
Enterprise Value to Revenue0.99
Price to book0.54

Upcoming events

Next earnings dayMay 2, 2025
Next dividend day—
Ex. dividend day—

News

Fulgent Genetics, Inc. (FLGT) Q1 Earnings and Revenues Beat Estimates

Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to loss of $0.01 per share a year ago.

Zacks Investment Research (May 2, 2025)
Jim Cramer does his homework on Fulgent Genetics

Cramer circled back to Fulgent Genetics after an investor asked him about the stock last week.

CNBC Television (November 17, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free